• EPH118 (HCRU)/Costs and Epidemiology of Patients With ADHD in Germany: A Claims Data Study (HEDDA)

    Dec 1, 2025, 00:00

  • EE527 Impact of CFTR Modulator Initiation on Direct Medical Costs for People With Cystic Fibrosis

    Dec 1, 2025, 00:00

  • Testing the Valuation of the EQ-5D-Y-5L in Adults and Adolescents: Results From a 5-Country Study and Implications for the Descriptive System

    Dec 1, 2025, 00:00

  • EE617 Procalcitonin-Guided Antimicrobial Stewardship for Sepsis and Lower Respiratory Tract Infections: A Budget Impact Analysis for the Perspective of the Patients in India

    Dec 1, 2025, 00:00

  • EE522 HPV-Related Disease Burden in Men and Women in the Czech Republic: A Claims Database Analysis

    Dec 1, 2025, 00:00

  • EE28 A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States

    Dec 1, 2025, 00:00

  • HSD48 Evaluation of the Article 51 VIGIE-AGE Experiment: A Significant Impact on Hospitalizations Resulting in Reduced Total Expenditure

    Dec 1, 2025, 00:00

  • EE439 Evaluating the Costs of Perioperative Iron-Deficiency Anemia Management in China: A Comparison of Ferric Derisomaltose, Ferric Carboxymaltose, and Usual Care

    Dec 1, 2025, 00:00

  • SA51 Impact of CIDP on Health-Related Quality of Life Fatigue and Daily Activities: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • HTA195 Impact of the Societal Perspective on HTA Decision Making in Rare Diseases

    Dec 1, 2025, 00:00

  • EE371 Economic Evaluation in the MENA Region (2015-2025): A Targeted Review of Methodological Rigor and Policy Relevance

    Dec 1, 2025, 00:00

  • CO91 Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis

    Dec 1, 2025, 00:00

  • OP15 Market Access AI Readiness: Maximizing Strategic Alignment Through Organizational Insights

    Dec 1, 2025, 00:00

  • EE48 An Evaluation of the Cost of Treatment for Low-Back Pain Among Patients Attending Public Healthcare Facilities in Nigeria

    Dec 1, 2025, 00:00

  • EPH61 Development of an Indicator-Based Framework for Epidemic Phase Classification in Emerging Respiratory Infectious Diseases

    Dec 1, 2025, 00:00

  • HPR53 Deliverables From 10 Years' Implementation of a National Health Technology Assessment System: Outcomes Sustainability Efficiency, Access, and Equity

    Dec 1, 2025, 00:00

  • Value-Based Commissioning of Mental Health Services in England: A Feasibility Study Using Multicriteria Decision Analysis

    Dec 1, 2025, 00:00

  • EE12 A Cost-Effectiveness Evaluation of Blinatumomab Use in the Measurable Residual Disease-Negative Remission State to Treat Adults With Philadelphia-Chromosome–Negative B-cell Acute Lymphoblastic Leukemia in France

    Dec 1, 2025, 00:00

  • HTA338 Tracing the Shift in Payer Evidence Expectations: A Review of AMCP Format Updates (2016-2024)

    Dec 1, 2025, 00:00

  • CO233 The Association Between COVID-19 Vaccination and the Healthcare Resource Use Related to COVID-19 in Typical Rural Residents in Japan

    Dec 1, 2025, 00:00

  • EE337 Disease Management Costs in Late-Line Metastatic Colorectal Cancer: A Portuguese Perspective Using Structured Expert Elicitation

    Dec 1, 2025, 00:00

  • PCR92 Exploring Knowledge Attitudes and Perspectives on Respiratory Viruses Vaccination Among Older Adults in the US

    Dec 1, 2025, 00:00

  • HPR182 Shifts in Medicine Reimbursement in Türkiye: Who Pays for Medicines (2015-2022)?

    Dec 1, 2025, 00:00

  • EE264 Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece

    Dec 1, 2025, 00:00

  • MSR56 Comparative Evaluation of Sequence-Encoding Strategies for Clustering Inhaled Therapy Pathways in COPD Patients Using Real-World Data

    Dec 1, 2025, 00:00

  • RWD180 The Impact of Socioeconomic and Clinical Factors on Mental Healthcare Expenditure: Enabling Quality Managed Care Decisions

    Dec 1, 2025, 00:00

  • HTA274 Pricing Analysis of Value-Added Medicines (VAMs) in Europe: A Call for Recognition of Patient-Centric Innovation

    Dec 1, 2025, 00:00

  • RWD31 Characterization of a Large-Scale Real-World Data Sour Impact of Linking Closed Claims With Electronic Health Record Data

    Dec 1, 2025, 00:00

  • RWD117 Leveraging Large Language Models and EMR Data to Identify Undiagnosed Rare Diseases: A Hybrid AI Approach

    Dec 1, 2025, 00:00

  • PCR137 Improving Time to Patient: Insights From the Canadian Cancer Treatment Hackathons

    Dec 1, 2025, 00:00

  • EE6 A Comparison of Treatment Costs for CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative HR+/HER2-: Early Breast Cancer (EBC) in Sweden

    Dec 1, 2025, 00:00

  • CO77 Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • RWD65 Disease Management in Adults with Type 1 Diabetes Who Have a Prior Type 2 Diabetes Misdiagnosis and Recorded HbA1c in a US Managed Care Population

    Dec 1, 2025, 00:00

  • HTA95 Cost-Effectiveness Analysis of RSVpreF Vaccine for RSV Prevention in Older Adults Under Situation of the National Vaccination Program in Taiwan: A Study on Economic and Clinical Advantages

    Dec 1, 2025, 00:00

  • HPR101 From Cost Containment to Modernization: Market Access Updates Across the EU4 and the UK in 2025

    Dec 1, 2025, 00:00

  • EE179 Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation From the Spanish Healthcare System Perspective

    Dec 1, 2025, 00:00

  • OP21 Scientific Outcome of ISPOR Conferences: An Analysis of 67,055 Abstracts Presented at 54 ISPOR Conferences Between 2002-2024

    Dec 1, 2025, 00:00

  • HPR236 Value of Patient-Reported Outcomes Data in Food and Drug Administration Labeling of Oncology Drugs to Payers in the United States

    Dec 1, 2025, 00:00

  • OP7 Exploring Value in Healthcare: Patient Satisfaction in Spain Before and After the Pandemic

    Dec 1, 2025, 00:00

  • CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment

    Dec 1, 2025, 00:00

  • EE744 Unlocking Value: Assessing the Cost-Effectiveness of Pitolisant Wakix®in Portugal

    Dec 1, 2025, 00:00

  • EE314 Cost-Utility of Protocoled Practice Nurse-Led Care for Children With Asthma in Primary Care

    Dec 1, 2025, 00:00

  • RWD56 Descriptive Comparison of Patient Characteristics and Treatment Patterns in Metastatic NSCLC: US and France Cohorts to Inform Transportability

    Dec 1, 2025, 00:00

  • HTA322 The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries

    Dec 1, 2025, 00:00

  • P2 Can AI-Assisted Data Extraction From HTA Reports Improve Comparative HTA Research: A Case Study on NICE Assessment Reports

    Dec 1, 2025, 00:00

  • MSR85 Empirical Evidence on Impact by Accounting for Cluster Effect Within Patients in Cohort Studies Evaluating Comparative Effectiveness of Dental Treatments: A Meta-Epidemiological Study

    Dec 1, 2025, 00:00

  • EE397 Economic Impact of Emicizumab vs. On-Demand Therapy With Bypassing Agents in Patients With Hemophilia A With Inhibitors in Mexico

    Dec 1, 2025, 00:00

  • RWD125 Millennial Medical Record (MMR) Data Profile: A Japanese Electronic Medical Records (EMRs) Database Utilizing Unstructured Data for Lung Cancer Research

    Dec 1, 2025, 00:00

  • SA18 Calibrating Large Language Model Probabilities to Achieve Target Recall in Systematic Review Screening

    Dec 1, 2025, 00:00

  • RWD81 Evolving Trends in Patient Demographics and Diagnosis in Gastric Cancer: A Real-World Analysis From US Community Oncology Practices From 2014 to 2024

    Dec 1, 2025, 00:00

  • EPH65 Drivers of Improvement in Observed Survival in Malignant Cancer Sites: A Cancer Registry Analysis

    Dec 1, 2025, 00:00

  • MSR165 Performance Evaluation of AI-Assisted Systematic Literature Review for Studies on Burden of HPV-Associated Head and Neck Cancers

    Dec 1, 2025, 00:00

  • P43 Cost-Effectiveness and Budget Impact of Gene Therapy for Eligible Patients With Sickle Cell Disease in the Netherlands

    Dec 1, 2025, 00:00

  • PCR58 Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version

    Dec 1, 2025, 00:00

  • RWD173 Short- and Longer-Term Healthcare Resource Utilization and Related Costs With Psoriasis in Brazilian Private Market

    Dec 1, 2025, 00:00

  • PCR230 The Estimation of Utility Weights From the Rett Syndrome Behavior Questionnaire

    Dec 1, 2025, 00:00

  • EE41 Adjuvanted RSVpreF3 Vaccine for Respiratory Syncytial Virus Prevention in the United Kingdom, Spain, and Australia: A Climate Change Impact Analysis

    Dec 1, 2025, 00:00

  • HTA292 Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain

    Dec 1, 2025, 00:00

  • EE627 Quantifying the Fiscal Benefits of Obesity Prevalence Reduction in China: A Public Economic Perspective

    Dec 1, 2025, 00:00

  • HPR181 Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024

    Dec 1, 2025, 00:00

  • EE545 Impacts of National Medical Insurance Negotiation on Antitumor Drug Utilization and Financial Burden: A City-Level Analysis in China

    Dec 1, 2025, 00:00

  • EE390 Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management

    Dec 1, 2025, 00:00

  • EPH128 Hospital Systemic Treatment for HepatoCarcinoma: The HOSTHECA Study

    Dec 1, 2025, 00:00

  • EE55 Assessing Conditional Cash Transfers for Tuberculosis Patients in India: An Extended Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HPR45 Clinical Outcome Assessments in Drug Approvals: Trends and Insights From FDA; EMA Labeling 2018-2023

    Dec 1, 2025, 00:00

  • CO232 Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • MT35 Potential Impacts of Improvement in Turnaround Time

    Dec 1, 2025, 00:00

  • SA60 Let LAMBA Do the Work: Can We Reduce Reliance on VBA in Health Economic Models?

    Dec 1, 2025, 00:00

  • HTA229 Maximizing Acceptance of Patient-Reported Outcome Data in German HTA Decision Making: Results From a Horizon Scan

    Dec 1, 2025, 00:00

  • HTA103 Defining Unavoidable Uncertainty in HTA: Towards More Flexible and Adapted Approaches for Promising Treatments

    Dec 1, 2025, 00:00

  • CO54 Comparative Efficacy and Safety of Avacincaptad Pegol vs. Pegcetacoplan in Treatment of Geographic Atrophy: Insights From a Multilevel Network Meta-Regression

    Dec 1, 2025, 00:00

  • Dec 1, 2025, 00:00

  • EE448 Evaluation of the Societal Impact of Emicizumab in France Since Its Market Authorization: Budget Impact From 2018 to 2024

    Dec 1, 2025, 00:00

  • EE74 Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective

    Dec 1, 2025, 00:00

  • HPR167 Publicly Funded Fertility Preservation Services for Medical Reasons in Selected Countries

    Dec 1, 2025, 00:00

  • EE375 Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH101 Experience of Pediatric Dental Screening in Hungary and in National Minority Groups in Romania

    Dec 1, 2025, 00:00

  • HTA241 Navigating Clinical Trial Design Under the EU Health Technology Assessment Regulation

    Dec 1, 2025, 00:00

  • CO230 Systematic Review of Prognostic Factors and Treatment Effect Modifiers for Transthyretin Amyloid Cardiomyopathy

    Dec 1, 2025, 00:00

  • MSR160 Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements

    Dec 1, 2025, 00:00

  • PCR170 Patient and Societal Preferences for On-Demand Treatment in Hereditary Angioedema: Estimation of Utility Using a Discrete Choice Experiment

    Dec 1, 2025, 00:00

  • EE692 The Cost-Effectiveness of an Artificial Intelligence Software for Stroke Imaging and Treatment Decisions in NHS Hospitals

    Dec 1, 2025, 00:00

  • EE52 Analysis of the Fiscal and Socioeconomic Impact of a National Social Program to Support In Vitro Fertilization in Romania: A Generational Accounting Model

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • CO104 Evaluating the Effectiveness of FitterLife: A Community-Based Virtual Weight Management Program for Overweight Adults Without Diabetes or Hypertension in Singapore

    Dec 1, 2025, 00:00

  • PCR169 Patient and Caregiver Recommendations for Person-Centered Oncology Clinical Trial Design: A Qualitative Study

    Dec 1, 2025, 00:00

  • EE455 Exploratory Assessment of the Societal Impact of Changing Informal Care Hours in the Netherlands

    Dec 1, 2025, 00:00

  • HTA81 Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?

    Dec 1, 2025, 00:00

  • RWD138 Primary Expenditure Drivers and Future Challenges From Emerging Technologies in Brazilian Private Market Real-World Data Analysis From a Brazilian Employer-Sponsored, Self-Insured Health Plan

    Dec 1, 2025, 00:00

  • EE706 The Economic Value of Diagnostic Strategies in Hepatitis D: A Methodological Review of Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • CO246 The Prevalence of COAs and DHTs for Studying Sleep Disorders in Clinical Trials

    Dec 1, 2025, 00:00

  • EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • CO127 Health Gains Associated With Homologous Recombination Deficiency Testing for Ovarian Cancer in South Korea: A Model-Based Analysis

    Dec 1, 2025, 00:00

  • EE97 Budget Impact Analysis of Subcutaneous Ocrelizumab for Relapsing Multiple Sclerosis in Italy: A Hospital Perspective

    Dec 1, 2025, 00:00

  • HTA13 A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal

    Dec 1, 2025, 00:00

  • CO126 Gene Expression Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Lymph Node-Positive Early Breast Cancer: A Systematic Review

    Dec 1, 2025, 00:00

  • HTA157 From the Outside Looking in: Patient Advocacy Groups' and Healthcare Providers' Perspectives on Patient Engagement Strategies in the Israeli Health Technology Assessment Process

    Dec 1, 2025, 00:00

  • MSR188 Single-Agent vs. Multi-Agent RAG for Health Economic Model Replication: A Comparative Evaluation

    Dec 1, 2025, 00:00

  • PCR258 Use of EORTC Item Lists for Patient-Reported Outcome Measurement in Industry-Sponsored Research: A Three-Year Snapshot of Study Characteristics

    Dec 1, 2025, 00:00

  • HTA192 IMF: The Innovative Medicines Fund or the Interim Medicines Fund?

    Dec 1, 2025, 00:00

  • MSR16 Advancing the Science of Qualitative Patient Preference Assessment Using Large Language Models

    Dec 1, 2025, 00:00

  • CO197 Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nirogacestat in Patients With Desmoid Tumors

    Dec 1, 2025, 00:00

  • EPH223 Survey of Depression Literacy and Help-Seeking Behavior Among Secondary School Students

    Dec 1, 2025, 00:00

  • PCR23 Assessing the Sensitivity of EQ-5D-5L and AQoL-4D to Disease Severity in Von Willebrand Disease: Findings From UK Cohort of the PIVOT-vWD Study

    Dec 1, 2025, 00:00

  • HPR59 Divergent Biologic Price Archetypes: Year-on-Year List Price Evolution Pre- and Post-Biosimilar Entry in the US, Europe, and Japan

    Dec 1, 2025, 00:00

  • HTA296 Scoping the Future: Using NICE Scopes to Inform PICO Prediction for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • PCR118 Health-Related Quality of Life in Patients With Metastatic Urothelial Cancer: Results of a Cross-Sectional Survey in Europe

    Dec 1, 2025, 00:00

  • EPH238 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Nonsquamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • CO239 The Effect of Nutritional Supplements on Semen Quality and Pregnancy Rates in Patients With Male Factor Infertility: A Systematic Literature Review and Network Meta-Analysis

    Dec 1, 2025, 00:00

  • RWD116 Leveraging a Multicountry Real-World Data Observatory to Monitor Respiratory Tract Infections and Evaluate Public Health Interventions in Europe

    Dec 1, 2025, 00:00

  • CO214 Robotic-Assisted Surgery Using the Da Vinci Surgical System in a Nordic Population: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • HSD104 Strengthening Routine Childhood Immunization Post-COVID: Global Strategies to Improve Coverage and Equity

    Dec 1, 2025, 00:00

  • HPR21 An Analysis of Possible Reference Countries for a US Most-Favored Nation Policy and Implications of Differences in Cost of Living on Global Drug Pricing Policies

    Dec 1, 2025, 00:00

  • EE162 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Dec 1, 2025, 00:00

  • HTA221 Life-Cycle Stage-Specific Prioritization of Joint Clinical Assessment PICOs: Balancing Access Potential Feasibility and Likelihood

    Dec 1, 2025, 00:00

  • MT18 From Development to Reimbursement Evidence-Generation Strategies for HealthTech in Europe

    Dec 1, 2025, 00:00

  • SA19 Characterizing Exploratory Endpoints in Early Oncology Trials: Insights From Trial Registry Audit

    Dec 1, 2025, 00:00

  • HTA242 Navigating Evidence Requirements for Joint Clinical Assessment (JCA): Practical Considerations for Systematic Literature Review (SLR) and Indirect Treatment Comparisons (ITCs)

    Dec 1, 2025, 00:00

  • EE311 Cost-Utility Analysis of Transcatheter Valve Replacement Using Valves With RESILIA Tissue for the Treatment of Aortic Stenosis in South Korea

    Dec 1, 2025, 00:00

  • RWD108 Integrating Agentic AI With LLM Workflows for Cohort Comparison in Healthcare Analytics

    Dec 1, 2025, 00:00

  • HTA61 Budget Impact Models in CEESP Opinions: A Decade of Insights

    Dec 1, 2025, 00:00

  • PT9 Mind the Gap: Understanding the Global Imbalances in Spending for Innovative Medicines

    Dec 1, 2025, 00:00

  • EE516 Healthcare Resource Utilization and Time Burden in Patients With Myelodysplastic Syndromes/Neoplasms Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

    Dec 1, 2025, 00:00

  • EE530 Impact Of Dupilumab Treatment On Healthcare Resource Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • MT33 Optimizing MASLD Diagnostic Protocols: A Microsimulation Analysis of Test Sensitivity Requirements

    Dec 1, 2025, 00:00

  • SA10 Alternative Evidence Generation Approaches for Rare Diseases: Addressing HEOR and Healthcare Decision-Making Challenges

    Dec 1, 2025, 00:00

  • EE424 Estimating the Clinical and Economic Value of Aztreonam-Avibactam for the Treatment of Metallo-Beta-Lactamase–Producing Carbapenem- Resistant Enterobacterales Infections in China: Adopting the STEDI Value Framework

    Dec 1, 2025, 00:00

  • HTA44 Assessing Readiness for the EU-HTA Regulation: Insights From Market Access Experts Across Europe

    Dec 1, 2025, 00:00

  • EE69 Assessment of the Economic and Societal Impact of Cervical Cancer Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • HTA93 Cost-Effectiveness Analysis of Gemcitabine Nabpaclitaxel Combination, Modified FOLFIRINOX, and SIROX As First-Line Therapy for Pancreatic Cancer

    Dec 1, 2025, 00:00

  • EE656 Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings

    Dec 1, 2025, 00:00

  • RWD103 Incidence of Adverse Events and Costs Among Patients Initiating Treatment for Myasthenia Gravis: A Real-World Analysis

    Dec 1, 2025, 00:00

  • HTA262 Overall Survival Adjusted for Subsequent Treatments: A Review of Health Technology Assessments

    Dec 1, 2025, 00:00

  • EE551 Indirect Costs Associated With Pneumococcal Disease: A Global Targeted Literature Review

    Dec 1, 2025, 00:00

  • HSD78 Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia

    Dec 1, 2025, 00:00

  • EE100 Budget Impact Analysis of the EPOCA Telemonitoring System for Elderly Patients in France

    Dec 1, 2025, 00:00

  • EE94 Budget Impact Analysis of Rozanolixizumab for the Treatment of Generalized Myasthenia Gravis (gMG) in Greece

    Dec 1, 2025, 00:00

  • PCR93 Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From Qualitative Patient and Caregiver Interviews

    Dec 1, 2025, 00:00

  • PCR89 Exploration of the Utility of Linguistic Validation Cognitive Debriefing Interviews in Generating Evidence for Adding or Modifying Source COA Content

    Dec 1, 2025, 00:00

  • Zero Dollar Copay Pharmacy Benefit Decreases Healthcare Expenditures Among Members With Type 2 Diabetes of Blue Cross Blue Shield of Louisiana

    Dec 1, 2025, 00:00

  • HPR87 Extension of the Mammographic Screening Program in Italy: Cost-Benefit Analysis and Impact of Early Diagnosis in the 45-74 Age Group

    Dec 1, 2025, 00:00

  • EE242 Cost-Effectiveness of Connected Injection Device for Pediatric Growth Hormone Deficiency in Spain: A Scenario-Based Microsimulation Analysis Using Real-World Data

    Dec 1, 2025, 00:00

  • HSD61 Impact on Prescribing Choice Following the Identification of Preferred Continuous Glucose Monitoring Sensors in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • P53 Exploring the Ability of Generative AI to Interpret and Report Comprehensive NMA Results: A Step Towards the Automation of NMA Reports

    Dec 1, 2025, 00:00

  • RWD118 Leveraging Large-Language Models for Medical Code List Creation: An Example Using the Charlson Comorbidity Index

    Dec 1, 2025, 00:00

  • MSR195 The AI-in-RWE Transparency (AIRT) Checklist: Essential and Desirable Standards for AI-Enhanced Real-World Evidence

    Dec 1, 2025, 00:00

  • EE257 Cost-Effectiveness of In-Hospital Motivational Smoking Cessation Counseling and Proactive Referral to Primary Care Follow-up

    Dec 1, 2025, 00:00

  • EPH215 Site-Specific Wastewater-Based Surveillance in Early Detection of COVID-19 New Cases and Prediction of Mass Testing Outcomes in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • HTA326 The Phantom Mena How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access

    Dec 1, 2025, 00:00

  • EE672 Stop Ignoring Missing Patients the Hidden Impact of Ignoring Missing Data in Health State Utility Estimation

    Dec 1, 2025, 00:00

  • MSR148 Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices

    Dec 1, 2025, 00:00

  • EE552 Indirect Treatment Comparisons in Economic Evaluations Submitted to the French Health Authority (CEESP) Since 2014

    Dec 1, 2025, 00:00

  • PCR82 Evaluating the Feasibility and Acceptability of a Personalized Endpoint: A Prospective Mixed Methods Study of Inventory-Facilitated Goal Attainment Scaling

    Dec 1, 2025, 00:00

  • SA56 Integrating Stakeholder Insights Into Thematic Analysis: Enhancing Efficiency and Supporting HEOR

    Dec 1, 2025, 00:00

  • HTA259 One Trial, Two Clocks: Coordinating EMA Assessment and Complementary EU HTA Evidence

    Dec 1, 2025, 00:00

  • EE715 The Impact of Real-World Standard-Dose Influenza Vaccine Effectiveness on the Cost-Effectiveness of High-Dose Influenza Vaccine: A Case Study in Japan

    Dec 1, 2025, 00:00

  • EE92 Budget Impact Analysis of Obecabtagene Autoleucel for Adults With Relapsed/Refractory B-cell ALL From a US Payer Perspective

    Dec 1, 2025, 00:00

  • HPR146 Navigating the Influence of Traditional Chinese Medicine (TCM) on the Positioning of New Treatments in China: A Review of TCM Inclusion in Clinical Guidelines

    Dec 1, 2025, 00:00

  • HPR144 Narrative Review of Total Quality-Adjusted Life Year (QALY) Gains From Oncology Medicines Reimbursed From 2020 To 2025 in Ireland

    Dec 1, 2025, 00:00

  • MSR120 How Chinese Restaurants Can Help With Robust Preference Insights: A Novel Dirichlet Mixture Model to Account for Complex Heterogeneity in Individual Preference Weights

    Dec 1, 2025, 00:00

  • EPH166 Mortality in COPD and Cardiovascular Disease Comorbidity: Survival Analysis Using Curated Data From Brazilian Public Healthcare System (SUS)

    Dec 1, 2025, 00:00

  • EE422 Estimating Quality-Adjusted Life Expectancy by Ethnicity for Application in Distributional Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EE187 Cost Savings From Patient Preference-Based Allocation of High-Efficacy Therapies for MS: Evidence From Switzerland

    Dec 1, 2025, 00:00

  • PCR175 Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care

    Dec 1, 2025, 00:00

  • PCR242 The Road Ahead: A Qualitative Study Mapping the Experience of Patients With Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • PT29 From Code to Quality: Identifying Quality Assurance Steps for AI Integration in Qualitative Healthcare Research: A Comparative Study of ChatGPT, Atlas.ti, and Traditional Coding

    Dec 1, 2025, 00:00

  • EE197 Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China

    Dec 1, 2025, 00:00

  • HPR131 Launches of Oncology Products in LATAM vs. the United States

    Dec 1, 2025, 00:00

  • HTA254 NICE Has Embraced Single-Arm Trials in Technology Appraisals but Where Is the Guidance?

    Dec 1, 2025, 00:00

  • MT7 Assessing the Economic Impact of a Robotic-Assisted Solution vs. a Manual Approach in Total Knee Arthroplasty in the UK

    Dec 1, 2025, 00:00

  • EE329 Digital Health Literacy, Engagement, and the Economics of Health Behavior: Evidence from the US HINTS Survey

    Dec 1, 2025, 00:00

  • PCR261 Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)

    Dec 1, 2025, 00:00

  • P49 Social and Economic Burden Among Patients With Inherited Retinal Disease: A Nationwide Matched Cohort Study in Sweden 2001-2021

    Dec 1, 2025, 00:00

  • PCR150 Looking Back to Go Forward: Reintegrating Scientific Considerations Into eCOA Design and Implementation

    Dec 1, 2025, 00:00

  • EE3 A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar

    Dec 1, 2025, 00:00

  • EPH87 Estimating the Eligible Population for Anti-Amyloid Therapy in Finland

    Dec 1, 2025, 00:00

  • EE2 A Budget Impact Analysis of Exclusive Human Milk Diet in Very Low Birth Weight Infants in Sheikh Shakhbout Medical City

    Dec 1, 2025, 00:00

  • MT46 Value of in Vitro Diagnostic IVD Tests in Health Society and Economy in Portugal

    Dec 1, 2025, 00:00

  • HTA354 Validation of a Natural Language Processing Solution (REALLI) Compared to Manual Review by Physicians of Electronic Health Records (EHR) From Patients With HER2+ Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EE287 Costs and Number Needed to Treat (NNT) to Achieve Improvements With C5 Inhibitors in Generalized Myasthenia Gravis From the Japanese Healthcare Perspective: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO43 Clinical Burden and Transfusion-Related Outcomes in Transfusion-Dependent Thalassemia in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00

  • EE169 Cost-Effectiveness of Nemolizumab in the Treatment of Patients With Moderate-to-Severe Prurigo Nodularis in Italy

    Dec 1, 2025, 00:00

  • HPR141 Melatonin Use Among Children and Adolescents: A Finnish Nationwide Drug Utilization Study

    Dec 1, 2025, 00:00

  • PT12 Understanding the Consequences of International Reference Pricing on Cancer Immunotherapy in Europe: A 10-Year Price Corridor Analysis

    Dec 1, 2025, 00:00

  • PCR239 The Rapid Involvement of Patients and the Public in Evidence Synthesis (RIPPLES) Framework: Development and Guidance

    Dec 1, 2025, 00:00

  • HSD6 Analysis of Pharmacists' Awareness on Post COVID-19 Conditions and Implementation in Postgraduate Education in Ukraine

    Dec 1, 2025, 00:00

  • EE616 Pricing Implications of Subcutaneous Reformulations Following Intravenous Launches: A Multicountry Analysis

    Dec 1, 2025, 00:00

  • PCR20 Are You Implementation Ready? An Alternative Patient And Healthcare System-Centered Model For Pharma

    Dec 1, 2025, 00:00

  • EE485 HDX vs. HDF in End-Stage Kidney Disease: Cost-Minimization Study in Saudi Arabia

    Dec 1, 2025, 00:00

  • P48 Empirical Comparison of Subjective Well-Being and Health-Related Quality of Life Measures in Australian Adolescents

    Dec 1, 2025, 00:00

  • HPR202 The Impact of Annual Price Revision Based on External Reference Pricing on Medicines Between 2012 and 2023 in Portugal

    Dec 1, 2025, 00:00

  • HPR173 Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • EPH231 The Cost of Complacency: Projecting the Burden of HIV Care in Eight European Countries

    Dec 1, 2025, 00:00

  • HTA314 The Development of the Multicriteria Decision Analysis in Specialized Burn Care: The Methodological Process

    Dec 1, 2025, 00:00

  • EPH48 Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study

    Dec 1, 2025, 00:00

  • EE154 Correlation Between Ultra-Orphan Drug Costs Cost-Effectiveness Metrics and Disease Prevalence

    Dec 1, 2025, 00:00

  • EPH131 Identifying CKD As a Key Driver of CVD Deaths

    Dec 1, 2025, 00:00

  • EPH268 Underlying Systemic Motifs That Prevent Diabetes Patients From Seeking and Utilizing Health Services in a Country With a High Prevalence of Diabetes

    Dec 1, 2025, 00:00

  • EE462 Feasibility Evaluation of Claims Database: Best Practices and Case Study for a Comparative Analysis of Robotic-Assisted Colorectal Surgery in Germany

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • EPH18 Are Anti-Obesity Drugs Life-Saving or Lifestyle Medicines? Reframing the Policy and Economic Debate

    Dec 1, 2025, 00:00

  • SA107 Zero-Shot RCT Identification Using Large Language Models: A Comparative Study With the Cochrane Classifier

    Dec 1, 2025, 00:00

  • CO182 Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • EPH182 Population-Level Impact of T-DM1 Use for HER2-Positive Early Breast Cancer According to National Clinical Practice Guidelines in Sweden

    Dec 1, 2025, 00:00

  • EE150 Conceptual Approach to Economic Modeling in Retinal Diseases: A Review and Critique of Two NICE Clinical Guidelines

    Dec 1, 2025, 00:00

  • EE582 Model Behavior: A Health Economics Checklist for Sales Models

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • EPH143 Incidence of Neutropenia Adverse Events Identified in Electronic Healthcare Records Among Initiators of CDK4/6 Inhibitors With Advanced Breast Cancer in the UK

    Dec 1, 2025, 00:00

  • HTA210 Integration of Germany’s AMNOG Framework With the Joint Clinical Assessment Process

    Dec 1, 2025, 00:00

  • EE518 Healthcare Resource Utilization in Patients With Non-Small Cell Lung Cancer (NSCLC) and Epidermal Growth Factor Receptor Mutation (eGFRm): A Retrospective Cohort Study in a Portuguese Comprehensive Cancer Center

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • EE680 System-Level Economic Impact of a Combination Influenza-COVID-19 Vaccine vs. Standalone Vaccinations in the United Kingdom

    Dec 1, 2025, 00:00

  • EE201 Cost-Effectiveness Analysis of GAAD Algorithm for Hepatocellular Carcinoma Surveillance of Cirrhotic Patients Using Italian Real-World Data

    Dec 1, 2025, 00:00

  • HTA239 Multicriteria Health Technology Assessments for High-Cost Oncology Drugs in Peru: A Cross-Sectional Study of RENETSA Records 2023-2024

    Dec 1, 2025, 00:00

  • HTA358 Weighting the OrPhar-SEFH MCDA Framework for Its Use in Ultrarare Kidney Diseases

    Dec 1, 2025, 00:00

  • HTA148 Fractional Polynomial Survival Models in HTA: An Exploratory Review of Use and Methodological Guidance Across Global Agencies

    Dec 1, 2025, 00:00

  • CO130 Health-Related Quality of Life (HRQoL) Impacts in Individuals With Hypophosphatasia (HPP): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HSD45 Ethical Implications of the Use of Artificial Intelligence (AI) Based Technologies for Medical Image Classification Systems in Screening: A Qualitative Systematic Review

    Dec 1, 2025, 00:00

  • SA95 The Journey to Diagnosis for Patients With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • MT24 Health Economic Evaluation Model for Ovarian Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • HTA194 Impact of the Introduction of the NICE Severity Modifier on HTA Outcomes of Oncology and Non-oncology Orphan Drugs

    Dec 1, 2025, 00:00

  • MSR191 Survival Extrapolations With and Without Incorporating External Eviden Evaluating the Performance of Bayesian M-Spline Models vs. Parametric Models in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Dec 1, 2025, 00:00

  • EE442 Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective

    Dec 1, 2025, 00:00

  • EPH73 Epidemiological Analysis of Colorectal Cancer in Cyprus Amidst the Absence of Organized Screening Programs Data From 2000 to 2020

    Dec 1, 2025, 00:00

  • EE635 Real-World Cost-Utility of Faricimab vs. Current and Future Anti-VEGF Therapies in Patients With Neovascular Age-Related Macular Degeneration in Italy

    Dec 1, 2025, 00:00

  • MSR100 Evaluation of the Use of ChatGPT in Data Extraction for Systematic Literature Reviews: Friend, Foe, or Fiction?

    Dec 1, 2025, 00:00

  • EPH203 Real-World Costs of United States Patients With T1 Diabetes, Removing Misdiagnosed Patients, and Compared With Patients With T1D and (T1.5 or T2) Diabetes

    Dec 1, 2025, 00:00

  • EPH13 An Exploration of the Incidence Rate of Anxiety and Depression Following a Diagnosis of Rheumatoid Arthritis Using the THIN Dataset

    Dec 1, 2025, 00:00

  • MSR156 NICE and CDA Assessment of Artificial Intelligence-Enabled Health Technologies: Analysis and Insights

    Dec 1, 2025, 00:00

  • EPH114 Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and HER, Population Census, and Cancer Registry Data in the United States

    Dec 1, 2025, 00:00

  • PCR69 Embedding Patient Experience Data (PED) in EU Joint Clinical Assessments: Strategic Imperatives and Evidence Practices

    Dec 1, 2025, 00:00

  • PT27 Synthetic Data Generation vs. Simulated Treatment Comparison: Assessment of the Performance of a Novel Approach for Unanchored Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • HPR166 Public Spending on Medicines Between 2018 and 2026: Lessons for Designing a New Financing Model in Portugal

    Dec 1, 2025, 00:00

  • EE623 Public Health Impact of Efluelda, a High-Dose Trivalent Influenza Vaccine (TIV-HD) Compared to Standard-Dose Trivalent Inactivated Vaccines (TIV-SD)

    Dec 1, 2025, 00:00

  • SA46 Get Real: A How-to Framework on Designing and Implementing a Regulatory and HTA-Grade External Comparator Study

    Dec 1, 2025, 00:00

  • MT27 Impact of Companion Diagnostics (CDx) on Reimbursement Outcomes of Breast Cancer and NSCLC Therapies

    Dec 1, 2025, 00:00

  • EE138 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • EE199 Cost-Effectiveness Analysis of Follow-up Strategies for Localized or Locally Advanced Renal Cell Carcinoma From the UK NHS Perspective

    Dec 1, 2025, 00:00

  • P57 Defining "Value" in Digital Health Interventions: A Triangulated Approach to Model Development

    Dec 1, 2025, 00:00

  • HSD58 How Do Neurologists Perceive the Organization and Functioning of Care in Their Multiple Sclerosis Units?

    Dec 1, 2025, 00:00

  • HSD65 Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India

    Dec 1, 2025, 00:00

  • MSR202 The Statistical Abyss: Real-World Evidence for Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE237 Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Ireland

    Dec 1, 2025, 00:00

  • HTA203 Insights on Progress Toward Patient-Centered HTA Through Evaluation of PRO Integration, Value Disconnects, and Policy Change in the EU5

    Dec 1, 2025, 00:00

  • HPR22 Analysis of ATC Equivalent Group and Therapeutic Reference Code Distributions Based on Drug Price and Reimbursement Lists in Türkiye Between 2020 and 2025

    Dec 1, 2025, 00:00

  • PCR200 Qualitative Trial Interviews to Explore the Experience of Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia

    Dec 1, 2025, 00:00

  • EE361 Economic Burden of Generalized Myasthenia Gravis (gMG) in Latin America (LA): A Microcosting Analysis of Direct Medical Costs (DMCs)

    Dec 1, 2025, 00:00

  • HTA290 Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?

    Dec 1, 2025, 00:00

  • MSR99 Evaluation of the Measurement Properties of the German LupusPRO™ for Swiss-German SLE Patients

    Dec 1, 2025, 00:00

  • MSR86 Ensuring Patient Inclusion When Baseline Is Missing: Utilizing Constrained Longitudinal Data Analysis (cLDA) for Patient-Reported Outcomes (PROs)

    Dec 1, 2025, 00:00

  • MSR17 Agentic-AI Analyzer to Chat With Your Excel-Based Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • EE105 Budget Impact of Azathioprine Metabolite Monitoring in Crohn’s Disease in Algeria

    Dec 1, 2025, 00:00

  • EPH245 The Incidence Mortality and Survival of Malignant Chondrosarcoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EE461 Faricimab vs. Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration: A Cost-Utility Analysis in Italy

    Dec 1, 2025, 00:00

  • EE580 Microsimulation Model to Estimate the Clinical and Cost Burden of Adverse Events Related to Long-Term Oral Corticosteroid Usage in Autoimmune Diseases in the United States

    Dec 1, 2025, 00:00

  • SA65 Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease

    Dec 1, 2025, 00:00

  • P55 Choosing Appropriate Population-Adjusted Indirect Comparison Methods for Health Technology Assessment: A Simulation Study on the Impact of Effect Modifiers Baseline Imbalances and Sample Size

    Dec 1, 2025, 00:00

  • MSR129 Improving Efficiency in Evidence Synthesis: Performance Assessment of Machine Learning Classifiers for Automated Screening in Systematic Literature Reviews

    Dec 1, 2025, 00:00

  • EPH209 Screening for Chronic Kidney Disease (CKD): A Systematic Review and Meta-Analysis of Trials and Quasi Experimental Studies

    Dec 1, 2025, 00:00

  • EPH179 Pharmacovigilance of Cannabis-Based Products in Brazil

    Dec 1, 2025, 00:00

  • HSD33 Differential Impact of Type 1 and Type 2 Diabetes on Families: A UK Cross-Sectional Study Using FROM-16

    Dec 1, 2025, 00:00

  • HTA347 Unmet Needs in NICE HTAs: Insights From Obesity and Diabetes Submissions

    Dec 1, 2025, 00:00

  • EPH96 Evidence-Driven Simulated Agents to Train Reinforcement Learning for Personalization in mHealth Interventions

    Dec 1, 2025, 00:00

  • EE282 Cost-Minimization Analysis and Economic Impact in EGPA: Evidence From MANDARA

    Dec 1, 2025, 00:00

  • MSR187 Simulation-Guided Trial Planning of a Cluster Randomized Trial With Probabilistic Covariate-Constrained Randomization for Vaccine Coverage

    Dec 1, 2025, 00:00

  • RWD62 Development and Validation of an Automated Cancer Stage Classifier for Real-World Oncology Data Mapped to the OMOP Common Data Model

    Dec 1, 2025, 00:00

  • EE592 Multistakeholder Engagement to Codevelop Specifications for Economic Models: The MASH Case Study

    Dec 1, 2025, 00:00

  • HPR112 Health Halo Effect in Supplement Marketing: A Content Analysis of Medical Claims in Community Pharmacies

    Dec 1, 2025, 00:00

  • HPR225 Trends in EMA-Approved New Medicines 2015-2024: New Mechanisms of Action and Regulatory Shifts

    Dec 1, 2025, 00:00

  • HTA82 Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece

    Dec 1, 2025, 00:00

  • PCR73 Enhancing Patient Engagement in Consensus Development: Global Insights From a Targeted Review of Digital Platforms and Methods

    Dec 1, 2025, 00:00

  • EE427 Estimating the Economic Burden of Potential Chikungunya Outbreaks in Southern Europe

    Dec 1, 2025, 00:00

  • EE594 NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases

    Dec 1, 2025, 00:00

  • SA26 Current Use of Hereditary Angioedema (HAE) Treatments in Sweden: An Analysis of the National Prescribed Drug Register

    Dec 1, 2025, 00:00

  • HTA298 Similarities and Differences Between the National Institute for Health and Care Excellence (NICE) and European Union Joint Clinical Assessment (EU JCA) Clinical Systematic Literature Review Requirements

    Dec 1, 2025, 00:00

  • SA86 Simulation of the Impact on LDLC Targets and Treatment Cost in High and Very High Cardiovascular Risk Patients of Cost-Based Sequencing of Lipid-Lowering Therapy

    Dec 1, 2025, 00:00

  • EE389 Economic Evaluation of the Breast Thermal Activity Indicator Plus Clinical Breast Examination

    Dec 1, 2025, 00:00

  • HPR71 Estimating Lost Life-Years and Quality-Adjusted Life-Years of Undertreatment of Patients With Renal Cell Carcinoma and Metastatic Pancreatic Cancer in England

    Dec 1, 2025, 00:00

  • EE755 When Cost-Effectiveness No Longer Counts: Industry Views on the Undermining of HTA Principles in Korea

    Dec 1, 2025, 00:00

  • CO243 The Impact on Life Expectancy of Delaying or Avoiding Type 1 Diabetes Using the Metabo-Reno-Cardiovascular Disease Model

    Dec 1, 2025, 00:00

  • HTA2 A Comparative Analysis of Reimbursement Decisions for Targeted Therapies and Immunotherapies in NSCLC Across EU HTA Bodies

    Dec 1, 2025, 00:00

  • EPH151 Is Greece on Track to Meet the 90% HPV Vaccine Coverage Rate Target by 2030? A Mathematical Modeling Study

    Dec 1, 2025, 00:00

  • EPH46 Clinical Functional Profile and Neuroimaging in Cerebral Palsy: A Population-Based Study

    Dec 1, 2025, 00:00

  • HTA356 Viable Reimbursement and Financing Models for mHealth Interventions in Sub-Saharan Africa: A Narrative Review

    Dec 1, 2025, 00:00

  • HTA258 Nutrieconomics: Concept and Expert Consensus on Health Technology Assessment of Nutritional Interventions in Brazil

    Dec 1, 2025, 00:00

  • HPR208 The Landscape of Antibiotic Development and Regulation in the United States and Europe, Alongside Evolving Industry Incentive Strategies

    Dec 1, 2025, 00:00

  • MSR133 Integrating Equity and Efficiency in Health Economic Evaluation: Development of Equity-Informed Methodologies in the French Healthcare Context (INEES Project)

    Dec 1, 2025, 00:00

  • CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study

    Dec 1, 2025, 00:00

  • EE460 Factors Associated With the Highest Costs Among US Adults With Primary Biliary Cholangitis

    Dec 1, 2025, 00:00

  • EE743 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Spain: A Return on Investment Analysis Using an Integrated Actuarial Macroeconomic Model

    Dec 1, 2025, 00:00

  • EE384 Economic Evaluation of Sodium Zirconium Cyclosilicate Lokelma for Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease in Egypt

    Dec 1, 2025, 00:00

  • PT8 Does Proposed IRP Introduction in the US Align With Current IRP Trends and With Best Practice Guidelines?

    Dec 1, 2025, 00:00

  • OP1 Bridging the Gap Between AI Principles and Practi A Comparative Evaluation of AI Position Statements and Frameworks for Responsible Use

    Dec 1, 2025, 00:00

  • EE569 Long-Term Impact of Emicizumab in Hemophilia A (HA): Analysis by Inhibitor Status in Three Latin American (LATAM) Countries

    Dec 1, 2025, 00:00

  • EE731 Therapeutic Drug Monitoring and Selective Use of Glucarpidase in High-Dose Methotrexate Therapy: A Cost Analysis From the Algerian Payer Perspective

    Dec 1, 2025, 00:00

  • EE640 Real-World–Based Cost-Effectiveness of Lipid-Lowering Therapies for ASCVD Patients With High CV Risk in Taiwan

    Dec 1, 2025, 00:00

  • CO242 The Impact of Network Meta-Analyses on HTA Decisions in Oncology: A Review of NICE Appraisals

    Dec 1, 2025, 00:00

  • RWD112 Landscape of Data Sources for Real-World Observational Studies: Focus on the French Context

    Dec 1, 2025, 00:00

  • PCR144 Investigation of the Impact of Hereditary Angioedema (HAE) on Health-Related Quality of Life: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • CO220 Subtyping Atopic Dermatitis Trajectories Using Digital Patient-Reported Outcomes and Machine Learning

    Dec 1, 2025, 00:00

  • EPH52 Cost-Effectiveness Analysis Of The 13-Valent And 20-Valent Pneumococcal Conjugate Vaccine In The Kazakh Adult Population

    Dec 1, 2025, 00:00

  • EE693 The Cost-Effectiveness of Imlifidase Idefirix® for Desensitization Treatment of Highly Sensitized Adult Kidney Transplant Patients in Ireland

    Dec 1, 2025, 00:00

  • MSR84 Empirical Comparison of Four Approaches for Generating Confidence Intervals Around Weighted Trial-Level Correlation

    Dec 1, 2025, 00:00

  • HPR51 Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany’s DIGA

    Dec 1, 2025, 00:00

  • HPR158 Perceived Impact and Actionability of Barriers to Drug Repurposing: Insights From a Multistakeholder Policy Survey

    Dec 1, 2025, 00:00

  • RWD85 FLAME: An Open-Source Federated Platform for Deeply Phenotyped and Multimodal Studies at Population Scale

    Dec 1, 2025, 00:00

  • CO231 Systematic Review of Prognostic Factors for Efficacy and Safety Outcomes in CAR-T Cell Therapy for Diffuse Large B-cell Lymphoma

    Dec 1, 2025, 00:00

  • EE96 Budget Impact Analysis of STRIDE (Tremelimumab + Durvalumab) vs. Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma: Qatari Payer and Societal Perspectives

    Dec 1, 2025, 00:00

  • MT31 National Competent Authorities’ Experiences With Early Feasibility Study Assessment: Promoting Dialogue, Supporting Sponsors, and Fostering Shared Learning to Harmonize the EU Framework

    Dec 1, 2025, 00:00

  • EE709 The Growing Importance of Reserve Antibiotics in Organ Transplant Care and the Role of Timely Appropriate Antibiotic Treatment to Preserve the Benefits of Prior Health Investments

    Dec 1, 2025, 00:00

  • RWD165 Real-World Treatment Patterns of Locally Advanced and Metastatic Urothelial Cancer (la/MUC) in Fran A Secondary Database Analysis

    Dec 1, 2025, 00:00

  • HPR58 Distributional Cost-Effectiveness Analysis: A Case Study of Obesity

    Dec 1, 2025, 00:00

  • EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial

    Dec 1, 2025, 00:00

  • CO61 Comparison of Bispecific T-cell Engager Antibodies and CAR-T Therapies for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA180 How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions

    Dec 1, 2025, 00:00

  • MSR3 A Generalizable Discrete Event Simulation Framework to Assess Clinical and Economic Impact of Prescription Protocol Revisions

    Dec 1, 2025, 00:00

  • HTA205 Integrating Health Equity Into Health Technology Assessment: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR233 Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • HPR30 Assessing the Potential Impact of NICE’s Updated HST Routing Criteria on Ultraorphan Drugs

    Dec 1, 2025, 00:00

  • EPH174 Out-of-Work Transitions in the European Population With Noncommunicable Diseases

    Dec 1, 2025, 00:00

  • PCR205 Real-World Drivers of Adherence in Obesity Highlight the Need for Patient-Centered Interventions

    Dec 1, 2025, 00:00

  • HPR224 Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25

    Dec 1, 2025, 00:00

  • HPR192 Ten Years of Portugal’s HTA System Through Stakeholder Eyes: Reflections and Future Priorities

    Dec 1, 2025, 00:00

  • CO200 Real-World Pharmacovigilance of Metoprolol: A Disproportionality Analysis of Adverse Events Using US FDA Adverse Event Reporting System (FAERS) and Bioinformatics

    Dec 1, 2025, 00:00

  • HTA107 Development and Validation of a Machine Learning Model for Predicting French HAS ASMR Ratings Using Product and Disease Characteristics

    Dec 1, 2025, 00:00

  • EE233 Cost-Effectiveness of Adjuvant Alectinib vs. Platinum-Based Chemotherapy in Resected Stage IB-IIIA ALK-Positive NSCLC: A French Health Economic Evaluation

    Dec 1, 2025, 00:00

  • RWD113 Landscape of Natural Language Processing (NLP) Capabilities at Clinical Sites: Insights From a Real-World (RW) Gastric Cancer (GC) Study

    Dec 1, 2025, 00:00

  • PCR259 Using Social Media Listening to Understand Oncology-Specific Patient Experiences: A Comparison of Pharmaceutical Industry-Funded vs. Nonpharmaceutical Industry-Funded Studies

    Dec 1, 2025, 00:00

  • EPH168 Mutagenicity of Imazalil, Pyrimethanil, and Thiabendazole With and Without Citrus Oil

    Dec 1, 2025, 00:00

  • MSR48 Bootstrap Methods for Confidence Interval Estimation in Small Samples: Implications for Health Economics

    Dec 1, 2025, 00:00

  • HTA145 Exploring Methodologies for Defining and Modeling Cure in Melanoma: Impacts on Estimating Cure Metrics

    Dec 1, 2025, 00:00

  • HSD20 Care Dependency and Sick Leave Patterns in Early Alzheimer's Disease: A Retrospective Claims Data Analysis in Germany

    Dec 1, 2025, 00:00

  • HTA208 Integrating Real-World Evidence for Advanced Therapies in Inflammatory Bowel Disease Into Reimbursement Submissions: Insights and Considerations From the UK

    Dec 1, 2025, 00:00

  • HSD82 Patient Blood Management Efficiency in Patients Subject to Orthopedic and Oncologic Elective Surgery

    Dec 1, 2025, 00:00

  • EE84 Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy

    Dec 1, 2025, 00:00

  • HTA270 Potential Implications of EU Joint Clinical Assessment (JCA) for the UK Affiliate of a Global Pharmaceutical Company

    Dec 1, 2025, 00:00

  • EE342 Does Modeling Adherence Matter? Insights From Prior NICE Appraisals

    Dec 1, 2025, 00:00

  • PCR209 Relevance of Quality Indicators for Supporting Patients’ Choice of Hospitals: An Online Survey

    Dec 1, 2025, 00:00

  • EE70 Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal

    Dec 1, 2025, 00:00

  • HPR114 How Health Policy Influences HTA Outcomes: Comparative Insights From Ukraine, Moldova, and Bulgaria

    Dec 1, 2025, 00:00

  • HPR10 A Strategic National Framework for Managed Entry Agreements to Access Innovative and Breakthrough Medications in Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR244 The Use of Patient-Reported Experience Measures in Adults With Obstructive Sleep Apnea: A Systematic Evidence Review

    Dec 1, 2025, 00:00

  • SA43 From Methods to Decisions: A Transparent Framework for Population-Adjusted Treatment Comparisons

    Dec 1, 2025, 00:00

  • EE115 Budgetary Impact of Generalized Pustular Psoriasis (GPP) in the Brazilian Private Healthcare System: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • SA38 Enhancing Targeted Literature Reviews (TLRs) with Artificial Intelligence (AI): A Methodological Approach for Conducting Efficient Targeted Searches

    Dec 1, 2025, 00:00

  • EE259 Cost-Effectiveness of Minocycline Intravenous for the Treatment of Serious Infections Due to Multidrug-Resistant Acinetobacter baumannii in Jordan

    Dec 1, 2025, 00:00

  • HTA248 Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions

    Dec 1, 2025, 00:00

  • PCR57 Describing the Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) on Patients and Their Caregivers: A Real-World Survey in Europe, the United States, and Japan

    Dec 1, 2025, 00:00

  • EE189 Cost Utility Analysis of a Digital Peer Navigation Program for Men With Prostate Cancer

    Dec 1, 2025, 00:00

  • HSD17 Burden of Healthcare Waste for European Hospitals: Findings From an AI-Based Literature Research

    Dec 1, 2025, 00:00

  • EE510 Healthcare Resource Utilization Among Adults With Pneumococcal Disease in England 2017-2022: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource

    Dec 1, 2025, 00:00

  • CO148 Incidence of Treatment-Related Adverse Events From Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • EPH280 Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco

    Dec 1, 2025, 00:00

  • MSR177 Qualitative Analysis of Results From a Delphi Study to Formalize a Treatment Protocol for Children With Early Diagnosed Duchenne Muscular Disease (DMD) Using Giles®, an Artificial Intelligence Agent for Healthcare Research

    Dec 1, 2025, 00:00

  • SA80 Real-World Cancer Treatments for Common Solid Tumors in China: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • MSR196 The AI-Only Workflow: Model and Report Adaptation Without Human Setup

    Dec 1, 2025, 00:00

  • HPR190 Staying Competitive in a Crowded Vaccine Market: Is There Room for a Third or Fourth Entrant in the Same Disease Area?

    Dec 1, 2025, 00:00

  • HTA218 Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec

    Dec 1, 2025, 00:00

  • EPH227 The Association Between Generalized Anxiety Disorder Symptom Severity and Comorbid Health Conditions Among the US General Adult Population

    Dec 1, 2025, 00:00

  • EE553 Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis

    Dec 1, 2025, 00:00

  • RWD53 Decoding Asthma: A Tale of Two Databases

    Dec 1, 2025, 00:00

  • EE607 Persistence to Basal Insulin and Economic Outcomes Among Patients With Type 2 Diabetes: A Retrospective Analysis Using Electronic Health Records in England

    Dec 1, 2025, 00:00

  • EE68 Assessment of the Cost Utility of Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Preterm Infants Born 29-35 Weeks' Gestational Age in the Philippines

    Dec 1, 2025, 00:00

  • RWD107 Institutional Trends and Healthcare Resource Utilization in Real-World NMIBC and MIBC Treatment in Germany

    Dec 1, 2025, 00:00

  • EE446 Evaluating the Performance of an Artificial Intelligence A-Powered Tool for Assessing Quality of Published Economic Evaluations: A Comparison With Human Reviewers Using the Drummond Checklist

    Dec 1, 2025, 00:00

  • HTA173 Health Technology Assessment (HTA) Systems and Risk Identification Strategies: A Comparative Analysis Across Western European Countries, Canada, and Australia

    Dec 1, 2025, 00:00

  • EE577 Methodological Challenges for the Economic Evaluation of Genomic Newborn Screening: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR210 The New Discount on Combination Drug Therapies in Germany: First Numbers and Assessment From a Payor Perspective

    Dec 1, 2025, 00:00

  • HPR162 Predicting the Maximum Fair Price (MFP) From Medicare Negotiations

    Dec 1, 2025, 00:00

  • EE34 A Systematic Literature Review on Costs and Healthcare Resource Utilization in Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • CO8 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin

    Dec 1, 2025, 00:00

  • CO20 Association Between ALK Tyrosine Kinase Inhibitor and the Risk of Interstitial Lung Disease and Pneumonitis in Non-Small Cell Lung Cancer Patients: A Systematic Review

    Dec 1, 2025, 00:00

  • HTA119 Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • P46 Eliciting Preferences for Combination Vaccines Protecting Against Multiple Respiratory Viruses: A Cross-Sectional Discrete Choice Experiment of Adults Aged 50 in the US

    Dec 1, 2025, 00:00

  • MSR206 Transporting Treatment Effects for Survival Outcomes Under Informative Censoring: A Simulation Study Using Summary-Level Data in the Target Population

    Dec 1, 2025, 00:00

  • EPH206 Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • MSR225 Win Ratio in the Presence of Censored Data: Can Probabilistic Variants Improve Robustness?

    Dec 1, 2025, 00:00

  • MSR141 Machine Learning for Missing Data Imputation in Healthcare Research: A Systematic Review of Methods and Applications

    Dec 1, 2025, 00:00

  • PCR88 Explaining Psychiatric Comorbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact

    Dec 1, 2025, 00:00

  • EE185 Cost per Responder Analysis of Teclistamab Compared to Real-World Physician’s Choice of Carfilzomib and/or Pomalidomide-Based Regimens for Triple-Class Exposed Patients With Refractory/Relapsed Multiple Myeloma

    Dec 1, 2025, 00:00

  • EE408 Embracing the Long-Term in Disruptive Health Innovations: A Strategic Necessity or a Necessary Evil? Cost Utility of Langerhans Islet Grafting in Unstable Type 1 Diabetes

    Dec 1, 2025, 00:00

  • HPR132 Leveling the Field: How the MFN Could Transform Drug Pricing

    Dec 1, 2025, 00:00

  • EPH159 Mapping of Treatment Patterns and Transfusion Status in Danish and Swedish Myelofibrosis (MF) Patients

    Dec 1, 2025, 00:00

  • MSR47 BHM and BHM-Based Extrapolations in an HTA Framework

    Dec 1, 2025, 00:00

  • CO237 The Clinical Burden of Fractures in Osteogenesis Imperfecta: A Systematic Review

    Dec 1, 2025, 00:00

  • EE31 A Review of Indirect Costs Within Economic Appraisals in France

    Dec 1, 2025, 00:00

  • PCR121 Health-Related Quality of Life of Patients With Epidermolysis Bullosa in Hungary: Results With the EQ-5D-5L and EQ-5D-Y-3L Preference-Based Measurement Tools

    Dec 1, 2025, 00:00

  • EE50 Analysis of Social and Economic Burden of Type 1 Diabetes Care in Italy

    Dec 1, 2025, 00:00

  • RWD154 Real-World Evidence in European Orphan Drug Submissions and the Impact on Reimbursement Success

    Dec 1, 2025, 00:00

  • CO260 Using Natural Language Processing to Identify Sequencing Patterns in Advanced Urothelial Carcinoma: A Real-World Observational Study

    Dec 1, 2025, 00:00

  • HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • MSR126 Identifying Risk Profiles for Early Treatment Discontinuation in Geographic Atrophy Using Machine Learning and SHAP Clustering

    Dec 1, 2025, 00:00

  • RWD143 Real-World Healthcare Resource Utilization and Related Costs Associated With Lung Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • EE724 The Socioeconomic Burden of Dengue in Spain

    Dec 1, 2025, 00:00

  • HPR119 Implementing Coverage With Evidence Development for Medicines With Uncertain Clinical Benefit: Insights From the Netherlands

    Dec 1, 2025, 00:00

  • EE542 Impact of SGLT2-Inhibitor Uptake in CKD Management in Denmark: A Decision Economic Model

    Dec 1, 2025, 00:00

  • EE249 Cost-Effectiveness of Etrasimod, Ozanimod, and Adalimumab Compared to Infliximab in Treatment-Naive Patients With Moderate to Severe Ulcerative Colitis

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »